John Shiver
Corporate Officer/Principal chez IGM BIOSCIENCES, INC.
Profil
John W.
Shiver is currently the Director at International AIDS Vaccine Initiative, Inc. He is also a Special Advisor at Impresa Management LLC and the Chief Strategy Officer-Infectious Diseases Unit at IGM Biosciences, Inc. Previously, he served as the President & Director at Sanofi Pasteur VaxDesign Corp.
He was also an Independent Director at Icosavax, Inc. from 2022 to 2024.
Additionally, he held the position of Vice President-Vaccine & Biologics Basic Research at Merck & Co., Inc. Dr. Shiver obtained his doctorate degree from the University of Florida in 1985 and his undergraduate degree from Wofford College in 1978.
Postes actifs de John Shiver
| Sociétés | Poste | Début |
|---|---|---|
| IGM BIOSCIENCES, INC. | Corporate Officer/Principal | 01/08/2021 |
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/09/2018 |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Consultant / Advisor | - |
Anciens postes connus de John Shiver
| Sociétés | Poste | Fin |
|---|---|---|
| ICOSAVAX, INC. | Directeur/Membre du Conseil | 19/02/2024 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
Sanofi Pasteur VaxDesign Corp.
 Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Sanofi Pasteur VaxDesign Corp. designs, develops, and manufactures in vitro models of the human immune system. The firm engages in preventing infectious disease by forecasting vaccine responses before clinical trials by providing predictive in vitro immunological models and assays. The company was founded by William Warren in 2004 and is headquartered in Orlando, FL. | President | - |
Formation de John Shiver
| University of Florida | Doctorate Degree |
| Wofford College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IGM BIOSCIENCES, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Sanofi Pasteur VaxDesign Corp.
Sanofi Pasteur VaxDesign Corp. Miscellaneous Commercial ServicesCommercial Services Sanofi Pasteur VaxDesign Corp. designs, develops, and manufactures in vitro models of the human immune system. The firm engages in preventing infectious disease by forecasting vaccine responses before clinical trials by providing predictive in vitro immunological models and assays. The company was founded by William Warren in 2004 and is headquartered in Orlando, FL. | Commercial Services |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
Icosavax, Inc.
 Icosavax, Inc. Pharmaceuticals: MajorHealth Technology Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. It focuses on developing vaccine candidates for viral causes of pneumonia in older adults. The company was founded by Neil King and David Baker on November 1, 2017 and is headquartered in Seattle, WA. | Health Technology |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Finance |
